Evidence map›Paper›PMID 25048973›Full record

ArticleFree radical biology & medicine2014

DNA double-strand breaks activate ATM independent of mitochondrial dysfunction in A549 cells.

Lidza Kalifa, Jennifer S Gewandter, Rhonda J Staversky, Elaine A Sia, Paul S Brookes, Michael A O'Reilly

Open access · greenAbstract read
In one paragraph

Article in Free radical biology & medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Whole genome transcriptomics reveal distinct atrial versus ventricular responses to neonatal hyperoxia.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  2. Manipulating and elucidating mitochondrial gene expression with engineered proteins.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2020
    Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lidza KalifaDepartment of Environmental Medicine, The University of Rochester, Rochester, NY 14642, USA.
Jennifer S GewandterDepartment of Anesthesiology, The University of Rochester, Rochester, NY 14642, USA.
Rhonda J StaverskyDepartment of Pediatrics, The University of Rochester, Rochester, NY 14642, USA.
Elaine A SiaDepartment of Biology, The University of Rochester, Rochester, NY 14642, USA.
Paul S BrookesDepartment of Anesthesiology, The University of Rochester, Rochester, NY 14642, USA.
Michael A O'ReillyDepartment of Pediatrics, The University of Rochester, Rochester, NY 14642, USA. Electronic address: michael_oreilly@urmc.rochester.edu.
University of Rochester · US

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI B Paige Lawrence · 1985 to 2026
$42.8M
Training in Environment ToxicologyT32ES007026 · NIEHS · UNIVERSITY OF ROCHESTER · PI Alison Elder, Marissa Sobolewski Terry · 1985 to 2026
$20.2M
MULTIDISCIPLINARY TRAINING IN PULMONARY RESEARCHT32HL066988 · NHLBI · UNIVERSITY OF ROCHESTER · PI GEORAS, STEVE N, O'REILLY, MICHAEL A · 2001 to 2021
$8.1M
SIRT1, Nitro-Lipids and CardioprotectionR01HL071158 · NHLBI · UNIVERSITY OF ROCHESTER · PI BROOKES, PAUL S · 2003 to 2025
$7.7M
Effect of Neonatal Hyperoxia on Alveolar Development and InfectionR01HL091968 · NHLBI · UNIVERSITY OF ROCHESTER · PI O'REILLY, MICHAEL A · 2009 to 2021
$5.4M
DNA Repair and Replication in Oxidant Lung InjuryR01HL067392 · NHLBI · UNIVERSITY OF ROCHESTER · PI O'REILLY, MICHAEL A · 2002 to 2014
$4.5M
NHLBI NIH HHS R01 HL067392NHLBI NIH HHS R01HL067392NHLBI NIH HHS R01 HL071158NHLBI NIH HHS R01HL071158NHLBI NIH HHS R01 HL091968NHLBI NIH HHS R01HL091968NHLBI NIH HHS T32 HL066988NHLBI NIH HHS T32HL66988NIEHS NIH HHS P30 ES001247NIEHS NIH HHS P30ES01247NIEHS NIH HHS T32 ES007026NIEHS NIH HHS T32ES07026
6 · The paper itself

Abstract

Excessive nuclear or mitochondrial DNA damage can lead to mitochondrial dysfunction, decreased energy production, and increased generation of reactive oxygen species (ROS). Although numerous cell signaling pathways are activated when cells are injured, the ataxia telangiectasia mutant (ATM) protein has emerged as a major regulator of the response to both mitochondrial dysfunction and nuclear DNA double-strand breaks (DSBs). Because mitochondrial dysfunction is often a response to excessive DNA damage, it has been difficult to determine whether nuclear and/or mitochondrial DNA DSBs activate ATM independent of mitochondrial dysfunction. In this study, mitochondrial and nuclear DNA DSBs were generated in the A549 human lung adenocarcinoma cell line by infecting with retroviruses expressing the restriction endonuclease PstI fused to a mitochondrial targeting sequence (MTS) or nuclear localization sequence (NLS) and a hemagglutinin antigen epitope tag (HA). Expression of MTS-PstI-HA or NLS-PstI-HA activated the DNA damage response defined by phosphorylation of ATM, the tumor suppressor protein p53 (TP53), KRAB-associated protein (KAP)-1, and structural maintenance of chromosomes (SMC)-1. Phosphorylated ATM and SMC1 were detected in nuclear fractions, whereas phosphorylated TP53 and KAP1 were detected in both mitochondrial and nuclear fractions. PstI also enhanced expression of the cyclin-dependent kinase inhibitor p21 and inhibited cell growth. This response to DNA damage occurred in the absence of detectable mitochondrial dysfunction and excess production of ROS. These findings reveal that DNA DSBs are sufficient to activate ATM independent of mitochondrial dysfunction and suggest that the activated form of ATM and some of its substrates are restricted to the nuclear compartment, regardless of the site of DNA damage.

Indexed as

DNA Breaks, Double-StrandedApoptosisAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell Line, TumorCell NucleusCell ProliferationChromosomal Proteins, Non-HistoneCyclin-Dependent Kinase Inhibitor p21Deoxyribonucleases, Type II Site-SpecificDNADNA RepairHumansMembrane Potential, MitochondrialMitochondriaPhosphorylationAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsChromosomal Proteins, Non-HistoneCTGCAG-specific type II deoxyribonucleasesCyclin-Dependent Kinase Inhibitor p21Deoxyribonucleases, Type II Site-SpecificDNAReactive Oxygen SpeciesRepressor ProteinsStructural Maintenance of Chromosome Protein 1TP53 protein, humanTRIM28 protein, humanTripartite Motif-Containing Protein 28Tumor Suppressor Protein p53ATMDNA damageFree radicalsMitochondrial dysfunctionOxidative stress

Identifiers

PMID25048973
PMCPMC4171189
OpenAlexW2013830376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.